GDP Contraction, the Fed, and the Dow Jones – Week of April 27 – May 1, 2020

By Kuldip K. Ambastha The Dow Jones had three down and two up days this week. The coronavirus pandemic has continued to wreak havoc all around the world, and the American capital markets were affected. During 1Q2020, the USA’s GDP (gross domestic product) annualized contraction rate was 4.8%. This figure was announced on Wednesday, April …

Jobs, Unemployment, and the Dow Jones – Week of March 30 – April 3, 2020

By Kuldip K. Ambastha The Dow Jones was up and down this week day by day, similar to what has been seen in the past few weeks. Due to the coronavirus pandemic and its related public health concerns around the world, massive changes have been seen in the USA and these changes have been affecting …

Government Stimulus and the Dow Jones – Week of March 23-27, 2020

By Kuldip K. Ambastha Per the table seen above, the Dow Jones Industrial Average (DJIA) took investors on a volatile ride this week. Down days were seen on Monday and Friday. Up days were seen on the Tuesday, Wednesday, and Thursday in between. This pattern in the DJIA was observed due to the federal government’s …

What Caught Our Attention in the Investment World? – Week of February 24-28, 2020

By Kuldip K. Ambastha and Anil K. Ambastha On Tuesday, February 25, 2020, the stock of Moderna, Inc. (MRNA) rose by 27.8% for the day. As the coronavirus (COVID-19) has spread around the world and led to a sell-off in the capital markets, Moderna, Inc. announced that its coronavirus vaccine candidate is scheduled to be …

What Caught Our Attention in the Investment World? – Week of November 18-22, 2019

By Kuldip K. Ambastha and Anil K. Ambastha Karuna Therapeutics Inc. (KRTX), a clinical-stage biopharmaceutical company, was founded in 2009 and is headquartered in Boston, MA. The company is focused on developing innovative therapies for individuals suffering from disabilities, disorders, and pain. Karuna Therapeutics Inc. has announced that its schizophrenia treatment’s Phase 2 clinical trial …

What Caught Our Attention in the Investment World? – Week of October 21-25, 2019

By Kuldip K. Ambastha and Anil K. Ambastha On October 22, 2019, Biogen Inc. (BIIB) delivered a 26.1% return for the day. This was the stock’s largest one-day percentage return in 23 years. Its Alzheimer’s drug (aducanumab) had previously been written off as a failure, but now will be getting a second chance at approval …